Evaluation of Bintrafusp Alfa in Operable and Untreated Head and Neck Squamous Cell Carcinoma (ICING)
A Phase II Trial Assessing Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in a Pre-operative Setting for Resectable and Untreated Head and Neck Squamous Cell Carcinoma
Sponsor: Merck KGaA, Darmstadt, Germany
Terminated
Sponsor decision following information on cases of hyperprogression and early toxicities with bintrafusp alfa in other studies
Other terminated trials from Merck KGaA, Darmstadt, Germany
Other Squamous Cell Carcinoma of Head and Neck trials with similar outcome
Listed as NCT04428047, this PHASE2 trial focuses on Squamous Cell Carcinoma of Head and Neck and remains terminated or withdrawn. Sponsored by Merck KGaA, Darmstadt, Germany, it has been updated 7 times since 2021, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
May 2022 — Jul 2024 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Apr 2021 — May 2022 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
▶ Show 2 earlier versions
-
Jan 2021 — Apr 2021 [monthly]
Not Yet Recruiting PHASE2
-
Jul 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Merck KGaA, Darmstadt, Germany
- UNICANCER
For direct contact, visit the study record on ClinicalTrials.gov .